Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in ... Read more

Ozempic® provided greater weight reductions for adults with a baseline BMI of or ... Read more

Tresiba® demonstrated significantly improved blood sugar control and lower rates ... Read more

Significant blood sugar improvement with Xultophy® compared to insulin glargine ... Read more

Oral semaglutide shows statistically significantly greater reductions in HbA1c a ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Novo Nordisk's investor and analyst event at ADA 2018, Orlando

Silent period,

Financial statement for the first six months of 2018,

Commerzbank Sector Conference, Frankfurt